Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies

Expert Review of Hematology

Volumn 5, Issue 6, 2012, Pages 661-669

  Riwes, Mary Mansour ^a   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspergillus; Candida; Empiric antifungal therapy; Galactomannan assay; Glucan assay; Hematologic malignancies; Hematopoietic stem cell transplant; Invasive fungal disease; PCR; Pre emptive antifungal therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIFUNGAL AGENT; BIOLOGICAL MARKER; FLUCONAZOLE; FUNGAL DNA; GALACTOMANNAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN DETECTION; ASPERGILLUS; BIOASSAY; BRONCHOSCOPY; CANDIDIASIS; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; ENDOSCOPY; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG ASPERGILLOSIS; LUNG BIOPSY; META ANALYSIS (TOPIC); MICROBIOLOGY; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; TREATMENT FAILURE;

ANTIFUNGAL AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES;

EID: 84870880680     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.53     Document Type: Review

References (73)

1. Pfaller MA, Pappas PG, Wingard Jr. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis 43 (1), S3-S14 (2006).
2. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8), 1068-1075 (2006).
3. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34(7), 909-917 (2002).
4. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161-1170 (2007).
5. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3), 197-205 (2009).
6. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidaemia and cancer: patients are not all the same. BMC Infect. Dis. 6, 50 (2006).
7. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325(18), 1274-1277 (1991).
8. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-preexposed cancer patients with positive cultures for aspergilli. Diagn. Microbiol. Infect. Dis. 52(1), 15-20 (2005).
9. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. 14(Suppl. 4), 5-24 (2008).
10. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49(9), 3640-3645 (2005).
11. Heussel CP, Kauczor HU, Heussel GE et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J. Clin. Oncol. 17(3), 796-805 (1999).
12. De Pauw B, Walsh TJ, Donnelly JP et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46(12), 1813-1821 (2008).
13. Preuner S, Lion T. Towards molecular diagnostics of invasive fungal infections. Expert Rev. Mol. Diagn. 9(5), 397-401 (2009).
14. Lease ED, Alexander BD. Fungal diagnostics in pneumonia. Semin. Respir. Crit. Care Med. 32(6), 663-672 (2011).
15. Wirk B, Wingard Jr. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 168(6), 299-311 (2009).
16. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin. Microbiol. Rev. 10(3), 444-465 (1997).
17. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect. Dis. 5(10), 609-622 (2005).
18. Ellepola AN, Morrison CJ. Laboratory diagnosis of invasive candidiasis. J. Microbiol. 43, 65-84 (2005).
19. Simoneau E, Kelly M, Labbe AC, Roy J, Laverdière M. What is the clinical significance of positive blood cultures with Aspergillus sp in hematopoietic stem cell transplant recipients? A 23 year experience. Bone Marrow Transplant. 35(3), 303-306 (2005).
20. Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Rácil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J. Antimicrob. Chemother. 66(Suppl. 1), i15-i24 (2011).
21. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol. 19(1), 253-259 (2001).
22. Barnes RA. Early diagnosis of fungal infection in immunocompromised patients. J. Antimicrob. Chemother. 61(Suppl. 1), i3-i6 (2008).
23. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis. 44(3), 373-379 (2007).
24. Maertens JA, Klont R, Masson C et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin. Infect. Dis. 44(10), 1329-1336 (2007).
25. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42(10), 1417-1427 (2006).
26. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20(7), 1898-1906 (2002).
27. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis. 190(3), 641-649 (2004).
28. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J. Clin. Microbiol. 48(4), 1255-1260 (2010).
29. Maertens J, Buvé K, Theunissen K et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115(2), 355-362 (2009).
30. Miceli MH, Grazziutti ML, Woods G et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46(9), 1412-1422 (2008).
31. Bergeron A, Belle A, Sulahian A et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 137(2), 410-415 (2010).
32. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J. Clin. Microbiol. 42(12), 5517-5522 (2004).
33. Nguyen MH, Leather H, Clancy CJ et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol. Blood Marrow Transplant. 17(7), 1043-1050 (2011).
34. Maertens J, Maertens V, Theunissen K et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin. Infect. Dis. 49(11), 1688-1693 (2009).
35. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based bronchoalveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br. J. Haematol. 121(3), 448-457 (2003).
36. Mikulska M, Furfaro E, Del Bono V et al. Piperacillin/tazobactam (Tazocin") seems to be no longer responsible for false-positive results of the galactomannan assay. J. Antimicrob. Chemother. 67(7), 1746-1748 (2012).
37. Viscoli C, Machetti M, Gazzola P et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J. Clin. Microbiol. 40(4), 1496-1499 (2002).
38. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40(12), 1762-1769 (2005).
39. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin- tazobactam. Clin. Infect. Dis. 38(6), 913-916 (2004).
40. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect. Dis. 4(6), 349-357 (2004).
41. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand. J. Infect. Dis. 42(6-7), 461-468 (2010).
42. Zandijk E, Mewis A, Magerman K, Cartuyvels R. False-positive results by the platelia Aspergillus galactomannan antigen test for patients treated with amoxicillin-clavulanate. Clin. Vaccine Immunol. 15(7), 1132-1133 (2008).
43. Mori Y, Nagasaki Y, Kamezaki K et al. High incidence of false-positive Aspergillus galactomannan test in multiple myeloma. Am. J. Hematol. 85(6), 449-451 (2010).
44. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J. Clin. Microbiol. 45(2), 676-677 (2007).
45. Chen SC, Kontoyiannis DP. New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr. Opin. Infect. Dis. 23(6), 567-577 (2010).
46. Mulanovich VE, Kontoyiannis DP. Fungal pneumonia in patients with hematologic malignancies: current approach and management. Curr. Opin. Infect. Dis. 24, 323-332 (2011).
47. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1->3)-β-d-glucan assay for invasive fungal disease. Clin. Infect. Dis. 49(11), 1650-1659 (2009).
48. Odabasi Z, Mattiuzzi G, Estey E et al. β-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39(2), 199-205 (2004).
49. Lamoth F, Cruciani M, Mengoli C et al.; Third European Conference on Infections in Leukemia (ECIL-3). b-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin. Infect. Dis. 54(5), 633-643 (2012).
50. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-β-d-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 43(12), 5957-5962 (2005).
51. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1->3)-β-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob. Agents Chemother. 50(10), 3450-3453 (2006).
52. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-β-d-glucan assay reactivity. Clin. Infect. Dis. 46(12), 1930-1931 (2008).
53. Pazos C, Pontón J, Del Palacio A. Contribution of (1->3)-β-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J. Clin. Microbiol. 43(1), 299-305 (2005).
54. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia. J. Clin. Microbiol. 47(2), 379-384 (2009).
55. Florent M, Katsahian S, Vekhoff A et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J. Infect. Dis. 193(5), 741-747 (2006).
56. Kami M, Fukui T, Ogawa S et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin. Infect. Dis. 33(9), 1504-1512 (2001).
57. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect. Dis. 9(2), 89-96 (2009).
58. Lau A, Chen S, Sorrell T et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J. Clin. Microbiol. 45(2), 380-385 (2007).
59. Spiess B, Seifarth W, Hummel M et al. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J. Clin. Microbiol. 45(11), 3743-3753 (2007).
60. Harrison E, Stalhberger T, Whelan R et al. Aspergillus Technology Consortium (AsTeC). Aspergillus DNA contamination in blood collection tubes. Diagn. Microbiol. Infect. Dis. 67(4), 392-394 (2010).
61. White PL, Bretagne S, Klingspor L et al. European Aspergillus PCR Initiative. Aspergillus PCR: one step closer to standardization. J. Clin. Microbiol. 48(4), 1231-1240 (2010).
62. Wingard Jr. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract. Res. Clin. Haematol. 20(1), 99-107 (2007).
63. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34(6), 730-751 (2002).
64. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52(4), 427-431 (2011).
65. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351(14), 1391-1402 (2004).
66. de Pauw BE. Between over- and undertreatment of invasive fungal disease. Clin. Infect. Dis. 41(9), 1251-1253 (2005).
67. Bennett JE, Powers J, Walsh T et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin. Infect. Dis. 36(Suppl. 3), 117-122 (2003).
68. Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 55(1), 2-16 (2012).
69. Cordonnier C, Pautas C, Maury S et al. Empirical versus pre-emptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 48(8), 1042-1051 (2009).
70. Hebart H, Klingspor L, Klingebiel T et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant. 43(7), 553-561 (2009).
71. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography- based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 41(9), 1242-1250 (2005).
72. Maertens J, Marchetti O, Herbrecht R et al.; Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. 46(5), 709-718 (2011).
73. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52(4), e56-e93 (2011).